@article {Benza220061, author = {Raymond L. Benza and David Langleben and Anna R. Hemnes and Anton Vonk Noordegraaf and Stephan Rosenkranz and Thenappan Thenappan and Paul M. Hassoun and Ioana R. Preston and Stefano Ghio and Roberto Badagliacca and Carmine D. Vizza and Irene M. Lang and Christian Meier and Ekkehard Gr{\"u}nig}, title = {Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension}, volume = {31}, number = {166}, elocation-id = {220061}, year = {2022}, doi = {10.1183/16000617.0061-2022}, publisher = {European Respiratory Society}, abstract = {Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.Raymond L. Benza (@OSUWexMed) and co-authors review the current evidence showing the effect of riociguat on right ventricle remodelling, function and structural parameters in preclinical models and patients with $\#$PAH or $\#$CTEPH. $\#$pulmonaryhypertension https://bit.ly/3Q9icVm}, issn = {0905-9180}, URL = {https://err.ersjournals.com/content/31/166/220061}, eprint = {https://err.ersjournals.com/content/31/166/220061.full.pdf}, journal = {European Respiratory Review} }